Curt Balch
YOU?
Author Swipe
View article: Lymphatic Metastasis of Esophageal Squamous Cell Carcinoma: The Role of NRF2 and Therapeutic Strategies
Lymphatic Metastasis of Esophageal Squamous Cell Carcinoma: The Role of NRF2 and Therapeutic Strategies Open
The lethality of esophageal squamous cell carcinoma (ESCC), and other epithelial cancers, is primarily due to its aggressive nature and frequent lymphatic metastasis, both of which impact prognosis. In this review, we explore the underlyin…
View article: CDK9 degradation Inhibits Gastroesophageal Cancer growth and Overcomes Radiation Resistance by Increasing Chromatin Accessibility and Downregulating YAP1/TEAD signaling
CDK9 degradation Inhibits Gastroesophageal Cancer growth and Overcomes Radiation Resistance by Increasing Chromatin Accessibility and Downregulating YAP1/TEAD signaling Open
Background Gastroesophageal cancer (GEAC) remains a major health burden and urgently needs novel therapeutic targets. The inhibition of CDK9’s activity holds the potential to be a highly effective anti-cancer therapeutic. However, the func…
View article: A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML
A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML Open
Although decitabine (DAC) shows activity against myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), patient responses are limited, and prognoses remain poor. Preclinical studies have indicated that arsenic trioxide (ATO) and …
View article: Spatial determinants of response to neoadjuvant radiotherapy and immunochemotherapy in locally advanced mismatch repair proficient rectal cancer
Spatial determinants of response to neoadjuvant radiotherapy and immunochemotherapy in locally advanced mismatch repair proficient rectal cancer Open
Although neoadjuvant chemoradiotherapy treatment followed by surgical resection is the recommended treatment for locally advanced rectal cancer (LARC), response rates remain poor. In proficient mismatch repair (pMMR) rectal cancer, combina…
View article: Tumor-Associated Macrophages as Major Immunosuppressive Cells in the Tumor Microenvironment
Tumor-Associated Macrophages as Major Immunosuppressive Cells in the Tumor Microenvironment Open
Within the tumor microenvironment, myeloid cells constitute a dynamic immune population characterized by a heterogeneous phenotype and diverse functional activities. In this review, we consider recent literature shedding light on the incre…
View article: Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond
Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond Open
Herpes simplex virus (HSV) has coevolved with Homo sapiens for over 100,000 years, maintaining a tenacious presence by establishing lifelong, incurable infections in over half the human population. As of 2024, an effective prophylactic or …
View article: A Narrative Review of Alternative Symptomatic Treatments for Herpes Simplex Virus
A Narrative Review of Alternative Symptomatic Treatments for Herpes Simplex Virus Open
Herpes simplex virus-1 (HSV-1) and -2 (HSV-2) are large, spherically shaped, double-stranded DNA viruses that coevolved with Homo sapiens for over 300,000 years, having developed numerous immunoevasive mechanisms to survive the lifetime of…
View article: Supplementary Figure 2 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Supplementary Figure 2 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide Open
PDF file, 2736KB, Niclosamide treatment (10mg/kg/daily) was given intraperitoneally every week one day after OTICs inoculation in NOD/SCID mice. Furthermore, Body weights remained constant during niclosamide treatment demonstrating a lack …
View article: Data from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Data from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide Open
A recent hypothesis for cancer chemoresistance posits that cytotoxic survival of a subpopulation of tumor progenitors drives the propagation of recurrent disease, underscoring the need for new therapeutics that target such primitive cells.…
View article: Supplementary Figure Legend from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Supplementary Figure Legend from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide Open
PDF file, 82KB.
View article: Supplementary Figure Legend from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Supplementary Figure Legend from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide Open
PDF file, 82KB.
View article: Data from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Data from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide Open
A recent hypothesis for cancer chemoresistance posits that cytotoxic survival of a subpopulation of tumor progenitors drives the propagation of recurrent disease, underscoring the need for new therapeutics that target such primitive cells.…
View article: Supplementary Table 1 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Supplementary Table 1 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide Open
PDF file, 27KB, Differential stem cell signaling between CP70 and CP70sps were compared using an RT-PCR pathway-focused arrays (Stem signaling/Wnt signaling). Red indicates gene upregulation while green indicates gene downregulation, in CP…
View article: Supplementary Figure 1 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Supplementary Figure 1 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide Open
PDF file, 1369KB, A, pretreatment of cells with the ABCG2 inhibitor GF120918 essentially eliminated the SP fraction of CP70 ovarian cancer cells (right panel). B, ovarian cancer CP70 SP spheroid-forming cells ("CP70sps cells"). CP70 SP cel…
View article: Supplementary Figure 3 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Supplementary Figure 3 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide Open
PDF file, 4382KB, One day after inoculation of 1�106 CP70 cells in NOD/SCID mice, niclosamide (10mg/kg/day) was administered intraperitoneally for three weeks, then twice a week for 2 weeks. After 9 weeks, mice were sacrificed, and tumor s…
View article: Supplementary Figure 1 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Supplementary Figure 1 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide Open
PDF file, 1369KB, A, pretreatment of cells with the ABCG2 inhibitor GF120918 essentially eliminated the SP fraction of CP70 ovarian cancer cells (right panel). B, ovarian cancer CP70 SP spheroid-forming cells ("CP70sps cells"). CP70 SP cel…
View article: Supplementary Figure 2 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Supplementary Figure 2 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide Open
PDF file, 2736KB, Niclosamide treatment (10mg/kg/daily) was given intraperitoneally every week one day after OTICs inoculation in NOD/SCID mice. Furthermore, Body weights remained constant during niclosamide treatment demonstrating a lack …
View article: Supplementary Figure 3 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Supplementary Figure 3 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide Open
PDF file, 4382KB, One day after inoculation of 1�106 CP70 cells in NOD/SCID mice, niclosamide (10mg/kg/day) was administered intraperitoneally for three weeks, then twice a week for 2 weeks. After 9 weeks, mice were sacrificed, and tumor s…
View article: Supplementary Table 1 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Supplementary Table 1 from Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide Open
PDF file, 27KB, Differential stem cell signaling between CP70 and CP70sps were compared using an RT-PCR pathway-focused arrays (Stem signaling/Wnt signaling). Red indicates gene upregulation while green indicates gene downregulation, in CP…
View article: Supplementary Table 1 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Supplementary Table 1 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors Open
Supplementary Table 1 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
View article: Data from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Data from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors Open
The objective of this study was to identify and characterize a self-renewing subpopulation of human ovarian tumor cells (ovarian cancer-initiating cells, OCICs) fully capable of serial propagation of their original tumor phenotype in anima…
View article: Supplementary Figure 2 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Supplementary Figure 2 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors Open
Supplementary Figure 2 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
View article: Supplementary Table 2 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Supplementary Table 2 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors Open
Supplementary Table 2 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
View article: Supplementary Table 1 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Supplementary Table 1 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors Open
Supplementary Table 1 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
View article: Supplementary Figure 1 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Supplementary Figure 1 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors Open
Supplementary Figure 1 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
View article: Supplementary Figure 1 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Supplementary Figure 1 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors Open
Supplementary Figure 1 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
View article: Supplementary Figure 2 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Supplementary Figure 2 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors Open
Supplementary Figure 2 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
View article: Data from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Data from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors Open
The objective of this study was to identify and characterize a self-renewing subpopulation of human ovarian tumor cells (ovarian cancer-initiating cells, OCICs) fully capable of serial propagation of their original tumor phenotype in anima…
View article: Supplementary Figure Legends 1-2 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Supplementary Figure Legends 1-2 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors Open
Supplementary Figure Legends 1-2 from Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors